California, Santa Cruz County greenlight J&J vaccinations to resume immediately
The CDC and FDA lifted their pause on Johnson & Johnson vaccinations Friday, and state and county officials followed suit Sunday morning.
Health providers locally and across California can again roll out Johnson & Johnson COVID-19 vaccines.
Following a CDC recommendation on Friday, the California Department of Public Health on Sunday morning concurred that the risk of serious blood clots caused by the vaccine is minimal.
As Santa Cruz County inches out of the pandemic, Lookout is chronicling the changes in our lives and the accomplishments of everyday people. “People in the Pandemic” is one of eight Lookout initiatives documenting all aspects of life amid COVID. For more, go to our COVID 2021 section, and sign up for COVID Text Alerts and our COVID PM newsletter here.
“said Dr. Erica Pan, the state epidemiologist. “ .
“More than half of Californians 16 and older have received one of the three vaccines available, and the one-shot Johnson & Johnson vaccine is also an important tool in our fight to stop the spread of COVID-19.”
Santa Cruz County and other Bay Area health departments, which have the final say on vaccine distribution within their jurisdictions, quickly concurred with the state’s recommendation. “The Johnson & Johnson vaccine is safe,” they said in a joint statement. “Bay Area health providers should resume its administration.”
We break big stories ...
Stay on top the news with Lookout text alerts and newsletters
Our news team prides itself on being first — and best. And we’ve got the stories to prove it.
Use of the J&J vaccine had been on pause since April 12.
The pause was prompted by six cases of a rare and perplexing clotting disorder seen among recipients of the single-shot vaccine. All six of those cases involved women between the ages of 18 and 48.
The blood clots were unusual because they were accompanies by a dangerously low level of platelets, the building blocks of blood clots.
The initial six cases rose to 15 when safety experts went back and reviewed records of adverse reactions to the vaccine. All of those cases were in women, and all but one of was under 50.
Even so, the panel said the risk was still tiny — effectively 1.9 cases per million people in the general population, or 7 cases per million women under 50.
Contributing: Los Angeles Times